Trials / Completed
CompletedNCT00002228
A Study of T-20 in HIV-Positive Adults
A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (planned)
- Sponsor
- Trimeris · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
Detailed description
Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enfuvirtide |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002228. Inclusion in this directory is not an endorsement.